On November 14 th, 2024, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported third quarter 2024 financial and operational results and filed its Form 10-Q with the SEC. Reviva provided ...

Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported preliminary results from its open label extension (OLE) portion of the Phase III RECOVER trial. Brilaroxazine showed a favorable long ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports.

Vandana Singh Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) shares are ...

CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the ...

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) was upgraded by research analysts at Maxim Group from a “hold” rating to a “buy” rating in a research note issued on Friday ...

Oppenheimer 35th Annual Healthcare Life Sciences Conference Format: Corporate update Date: Wednesday, February 12, 2025 Time: 2:40 p.m. ET Location: Virtual Webcast Link: Click Here ...

Short interest in Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH) decreased during the last reporting period, falling from 5.64M to 5.22M. This put 12.54% of the company's publicly available ...

1 Day RVPH 1.06% DJIA -0.32% Russell 2K -0.30% Health Care/Life Sciences -0.52% ...